Pfizer Inc PFE

Alternate Symbol(s): N.PFE

Healthcare

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.

NYSE:PFE - Post by User

Pfizer Inc > Pfizer Going It Alone

<< Previous

Bullboard Posts

Next >>

Post by JohnT121on Mar 29, 2021 2:45pm

130 Views

Post# 32899666

Pfizer Going It Alone

Pfizer will now go it alone in vaccine expansion without BioNTech. They see the potential in developing MRNA vaccines for all types of future treatments. Annual COVID MRNA vaccines would be used globally and worth billions per year. This alone would translate into substaintial new recurring revenues per year for PFE .

Also working on an oral vaccine which would be a game changer, pre-clinical studies show positive results for SARS-CoV-2 and future viruses as well.

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity